8-K: Cellectar Biosciences Reports Strong Clinical Trial Results for Iopofosine and Advances Novel Radiopharmaceutical Candidates

Cellectar Biosciences announced positive clinical data for its lead drug candidate, iopofosine, in multiple cancer types, alongside plans to advance two new radiopharmaceutical candidates, CLR 125 and CLR 225, into Phase 1 studies, contingent on securing additional financing.

Summary

• Cellectar Biosciences provided updated disclosures regarding its drug candidates and clinical trial progress in connection with a proposed securities offering.
• CLR 125, an Auger-emitting radiopharmaceutical, showed good activity in multiple solid tumor models, especially triple-negative breast cancer (TNBC), with high tumor uptake and minimal toxicities in preclinical studies.
• A Phase 1b dose-finding study for CLR 125 in advanced TNBC is planned for the second half of 2025, with an anticipated enrollment of up to 75 patients across three dose levels.
• CLR 225, an alpha-emitting radiopharmaceutical, demonstrated activity in pancreatic, colorectal, and breast cancer animal models, showing excellent biodistribution and tumor uptake with no adverse events at highest doses.
• A Phase 1 imaging and dose escalation safety study for CLR 225 is prepared to initiate in the second half of 2025.
• The CLOVER-WaM study for iopofosine in relapsed/refractory Waldenstrom's Macroglobulinemia (WM) met its primary endpoint with a major response rate (MRR) of 58.2% (95% CI [44.50%, 75.80%], p < 0.0001), significantly exceeding the FDA-agreed 20% hurdle.
• In CLOVER-WaM, the overall response rate (ORR) was 83.6%, and 98.2% of patients achieved disease control; responses were durable with median duration of response not reached at 11.4 months follow-up and 76% of patients remaining progression-free at 8 months.
• Iopofosine I 131 monotherapy achieved a 7.3% complete remission (CR) rate in the highly refractory WM population, with 73.8% of patients having prior exposure to a BTKi and 77.1% being refractory to BTKis.
• Iopofosine I 131 was well tolerated in CLOVER-WaM, with common Grade 3 or higher treatment-related adverse events (TRAEs) including thrombocytopenia (81.5%), neutropenia (66.2%), and anemia (47.7%); all patients recovered from cytopenias, and there were no treatment-related deaths.
• Preliminary data from a Phase 1 study combining iopofosine with external beam radiation treatment (EBRT) in relapsed/refractory Head and Neck Cancer (HNC) showed a 64% complete remission rate and 73% ORR (n=11), with durable tumor control (73% overall survival, 36% progression-free survival at 12 months).
• The CLOVER-2 Phase 1b pediatric study for iopofosine in relapsed/refractory high-grade gliomas is partially funded by a ~$2 million National Institutes of Health (NIH) SBIR grant.
• The proposed offering of securities is intended to provide capital for operating expenses and to initiate the CLR 125 Phase 1b clinical study.

Sentiment

Score: 8

Explanation: The document presents very strong positive clinical trial results for iopofosine in multiple indications, exceeding industry benchmarks. Promising preclinical data for new candidates (CLR 125, CLR 225) are also highlighted. The primary negative is the stated dependence on additional financing for future studies, and the mention of past fatalities with iopofosine, but the overall tone and data are highly encouraging for the company's pipeline.

Positives

• CLOVER-WaM study for iopofosine in WM met its primary endpoint with a major response rate (MRR) of 58.2%, significantly exceeding the FDA-agreed 20% hurdle.
• The overall response rate (ORR) in CLOVER-WaM was 83.6%, and 98.2% of patients experienced disease control, indicating high efficacy.
• Responses in CLOVER-WaM were durable, with median duration of response not reached at 11.4 months of follow-up and 76% of patients remaining progression-free at a median follow-up of eight months.
• Iopofosine I 131 monotherapy achieved a 7.3% complete remission (CR) rate in a highly refractory WM patient population.
• Iopofosine I 131 was well tolerated in CLOVER-WaM, with no treatment-related deaths and all patients recovering from cytopenias.
• The Phase 1 study combining iopofosine with EBRT in relapsed/refractory Head and Neck Cancer (HNC) showed strong efficacy with a 64% complete remission rate and 73% ORR (n=11).
• The HNC study demonstrated durability of tumor control with 73% overall survival and 36% progression-free survival at 12 months.
• Preclinical evaluations of CLR 125 showed good activity in multiple solid tumor models, especially triple-negative breast cancer, with high tumor uptake and minimal toxicities.
• Preclinical evaluations of CLR 225 demonstrated activity in pancreatic, colorectal, and breast cancer models, with excellent biodistribution and tumor uptake, and no adverse events at the highest doses tested.
• The CLOVER-2 Phase 1b pediatric study is partially funded by a ~$2 million NIH SBIR grant, reducing immediate capital needs for this program.

Negatives

• Fatalities have occurred in patients post-treatment with iopofosine in the CLOVER-1 Phase 2b study.
• Initiation of Phase 1b study for CLR 125 and Phase 1 study for CLR 225 is subject to the company's ability to obtain additional financing.
• Common Grade 3 or higher treatment-related adverse events (TRAEs) observed in CLOVER-WaM included thrombocytopenia (81.5%), neutropenia (66.2%), and anemia (47.7%).
• Common Grade 3 or higher TRAEs in the HNC study included thrombocytopenia (75%), lymphopenia (75%), leukopenia (75%), neutropenia (67%), and anemia (42%).

Risks

• The initiation of planned Phase 1b clinical study for CLR 125 and Phase 1 study for CLR 225 is contingent on the company's ability to obtain additional financing.
• Fatalities have occurred in patients post-treatment with iopofosine in the CLOVER-1 Phase 2b study, indicating potential severe adverse events.
• Patients in clinical trials for iopofosine experienced significant hematologic toxicities (e.g., thrombocytopenia, neutropenia, anemia, leukopenia, lymphopenia) and non-hematologic toxicities (e.g., fatigue, nausea, diarrhea), which could impact patient safety and treatment adherence.
• The highly refractory nature of the patient populations in the CLOVER-WaM and HNC studies means that future trials in broader or less refractory populations might yield different results.
• The efficacy and safety profile of CLR 125, while chemically similar to iopofosine, may differ due to the different physical properties of its emissions, potentially leading to unexpected side effects.

Future Outlook

The company plans to initiate a Phase 1b dose finding study for CLR 125 in triple-negative breast cancer and a Phase 1 imaging and dose escalation safety study for CLR 225 in the second half of 2025, both contingent on securing additional financing. The CLOVER-1 Phase 2b study for iopofosine in highly refractory MM and CNSL patients is closed to enrollment but remains ongoing with patients in follow-up.

Management Comments

• "The Company believes that [Auger emitters'] precision means that to cause the necessary breakage of the tumor cell DNA, the isotope must get inside the cell and near the cell nucleus to be effective."
• "The Company believes that CLR 125 achieves this due to the Company’s novel phospholipid ether drug conjugate platform."
• "Given the different physical properties of the emissions from CLR 125, the Company believes that side effects could be less [compared to iopofosine]."
• "We believe that these data support the notion of enhanced patient outcomes when combining the use of iopofosine I 131 in combination with external beam radiation for a treatment of solid tumors."

Industry Context

This announcement highlights Cellectar's continued focus on developing targeted radiopharmaceuticals for difficult-to-treat cancers, including highly refractory B-cell malignancies, triple-negative breast cancer, and head and neck cancer. The development of Auger and alpha-emitting agents (CLR 125, CLR 225) represents an advancement in precision radiotherapy, aiming to deliver highly localized radiation with potentially reduced systemic toxicity. The positive results for iopofosine in Waldenstrom's Macroglobulinemia and Head and Neck Cancer address significant unmet medical needs in these patient populations, particularly those who have failed multiple prior therapies.

Comparison to Industry Standards

• The CLOVER-WaM study's major response rate (MRR) of 58.2% significantly exceeds real-world data, which typically demonstrates a 4-12% MRR in a less pretreated patient population.
• The median duration of response (DOR) in CLOVER-WaM was not reached with 11.4 months of follow-up, and 76% of patients remained progression-free at a median follow-up of eight months, which compares favorably to real-world data showing a DOR of approximately six months or less despite continuous treatment.

Stakeholder Impact

• Shareholders: Potential positive impact due to strong clinical trial results and advancement of pipeline, but also potential dilution from the proposed securities offering.
• Patients: Potential for new, effective treatment options for highly refractory cancers, particularly Waldenstrom's Macroglobulinemia, triple-negative breast cancer, and head and neck cancer.
• Employees: Continued operations and potential growth opportunities if new studies are funded and successful.
• Creditors: The proposed capital raise could improve the company's financial stability, potentially reducing credit risk.

Next Steps

• Initiate a Phase 1b dose finding study for CLR 125 in advanced triple-negative breast cancer in the second half of 2025, subject to obtaining additional financing.
• Initiate a Phase 1 imaging and dose escalation safety study for CLR 225 in the second half of 2025, subject to obtaining additional financing.
• Continue follow-up for patients in the CLOVER-1 Phase 2b study for iopofosine in highly refractory MM and CNSL.

Key Dates

Recommendation

Keywords

Cellectar Biosciences, CLRB, radiopharmaceuticals, oncology, cancer treatment, clinical trials, iopofosine, CLR 125, CLR 225, Waldenstrom's Macroglobulinemia, triple negative breast cancer, head and neck cancer, pancreatic cancer, targeted radiotherapy, Auger emitters, alpha emitters, SEC filing, drug development